Quarterly report · Q2
4587.TEDINET S100OZ1E
Period2022-01-01 → 2022-06-30
Filed2022-08-10
StandardIFRS
ConsolidatedYes
Data checks17 of 17 passed
Key figures · 65
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.0bn | 2022-01-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥4.6bn | 2022-04-01 → 2022-06-30d | Cons. | Revenue IFRS |
| Revenue | ¥9.4bn | 2021-01-01 → 2021-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.9bn | 2021-01-01 → 2021-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥1.4bn | 2021-04-01 → 2021-06-30d | Cons. | Revenue IFRS |
| Operating income | −¥1.6bn | 2022-01-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥393m | 2022-04-01 → 2022-06-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥436m | 2021-01-01 → 2021-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥442m | 2021-04-01 → 2021-06-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥1.5bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥361m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.8bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥312m | 2021-01-01 → 2021-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥352m | 2021-04-01 → 2021-06-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥1.1bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥227m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥2.6bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥8m | 2021-01-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥213m | 2021-04-01 → 2021-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥1.1bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | −¥227m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss IFRS |
| Net income | ¥2.6bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥8m | 2021-01-01 → 2021-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥213m | 2021-04-01 → 2021-06-30d | Cons. | Profit loss IFRS |
| Total assets | ¥51.9bn | at 2022-06-30 | Cons. | Assets IFRS |
| Total assets | ¥27.0bn | at 2021-12-31 | Cons. | Assets IFRS |
| Total assets | ¥24.8bn | at 2021-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥26.1bn | at 2020-12-31d | Cons. | Assets IFRS |
| Total liabilities | ¥27.2bn | at 2022-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.7bn | at 2021-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥4.9bn | at 2020-12-31d | Cons. | Liabilities IFRS |
| Net assets / equity | ¥24.7bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥25.4bn | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥22.6bn | at 2021-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥21.3bn | at 2020-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥24.7bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥25.4bn | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥22.6bn | at 2021-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥21.3bn | at 2020-12-31d | Cons. | Equity attributable to owners of parent IFRS |
| Cash & equivalents | ¥6.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.7bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.8bn | at 2021-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥7.1bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥10m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥6.7bn | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥5.0bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥26.7bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥2.3bn | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥450m | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥21.6bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥66m | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥45m | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-8.13 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-1.75 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥19.96 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-0.07 | 2021-01-01 → 2021-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥1.66 | 2021-04-01 → 2021-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-8.13 | 2022-01-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-1.75 | 2022-04-01 → 2022-06-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥19.81 | 2021-01-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-0.07 | 2021-01-01 → 2021-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥1.64 | 2021-04-01 → 2021-06-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 47.7% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 93.8% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 91.3% | at 2021-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 9
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥1.1bn |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥1.1bn |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥1.4bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥198m |
| —segment total | revenue | 2022-01-01 → 2022-06-30 | ¥5.0bn |
| —segment total | revenue external | 2022-01-01 → 2022-06-30 | ¥5.0bn |
| —segment total | segment profit | 2022-01-01 → 2022-06-30 | −¥1.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 668
| Item | Context | Value | Unit |
|---|---|---|---|
| Condensed quarterly consolidated statement of changes in equity IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of cash flows IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes reporting entity condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes basis of preparation condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant accounting policies condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Disclosure of changes in reportable segments IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that companys business comprises single segment IFRS | Prior1YTDDuration | Original text (Japanese)前第２四半期連結累計期間における当社グループは創薬開発事業のみの単一セグメントのため、記載を省略しております。 | |
| Notes business combinations condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes earnings per share condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes bonds and borrowings condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes financial instruments condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes contingent liabilities condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes subsequent events condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes first time adoption condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 17 of 17 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |